Madan Jagasia

Company: Obsidian Therapeutics

Job title: Chief Executive Officer

Bio:

Madan Jagasia, M.D., M.S., is Obsidian’s Chief Executive Officer. Dr. Jagasia is a highly experienced physician executive with an extensive oncology and cell therapy-focused clinical background and deep industry experience developing tumor-infiltrating lymphocyte (TIL) treatments for cancer. Prior to joining Obsidian, Dr. Jagasia was Executive Vice President, Medical Affairs at Iovance Biotherapeutics, where he was responsible for managing national medical affairs, strategic congress planning, advocacy, strategic alliances and external research collaborations. Before Iovance, he was Chief Medical Officer and Executive Medical Director of Cancer Patient Care Center, Vanderbilt-Ingram Cancer Center (VICC), where he co-led Translational Research and Interventional Oncology Research Program at VICC. Dr. Jagasia began his career as a faculty member in the Division of Hematology-Oncology at Vanderbilt University Medical Center. Dr. Jagasia has his M.B.B.S from the GS Medical College & KEM Hospital, an M.S. and a Master of Management in Health Care from Vanderbilt University.

Seminars:

OBX-115 Engineered TIL Cell Therapy with Regulatable Membrane-Bound IL15: Initial Multicenter Clinical Trial Results in Advanced Melanoma 8:30 am

OBX-115 TIL is engineered to express membrane-bound IL15 regulated by acetazolamide, abrogating the need for IL2 OBX-115 is compatible with low-dose lymphodepletion and has a positively differentiated safety profile At RP2D, OBX-115 can induce deep and durable responses in patients with ICIresistant advanced melanomaRead more

day: Conference Day One AM

Fireside Chat: Clinical Data & Reflections on the Current State of TIL Therapies in the Clinic 10:00 am

Examining the latest clinical insights shaping TIL therapy to better understand the direction of innovation in the field Discussing real-world challenges and opportunities in TIL development to uncover practical strategies for accelerating progress Envisioning the future of TIL therapies through expert perspectives to inform more effective research and clinical decisionsRead more

day: Conference Day One AM